CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 64 enrolled
Drug / intervention
Blood sampling - healthy volunteers +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02565082
NCT02565082N/ACompleted

Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients

Brugmann University Hospital·interventional·Posted Oct 1, 2015·Updated Jul 26, 2016

In Brief

A clinical study evaluating Blood sampling - healthy volunteers, Blood sampling - sickle cell patients arm - stable condition, and 2 other interventions for Sickle Cell Disease. Completed, enrolled 64 participants across 1 site.

Detailed Summary

Sickle cell disease is a genetic disorder caused by a point mutation on the amino acid sequence of the β chain of hemoglobin. The most expressive and most frequent complication of the disease is vaso-occlusive crisis, dominated by a painful syndrome. In addition to vaso-occlusive crises, many more chronic biological disturbances are observed in sickle cell patients.Sickle cell disease is considered nowadays as a hypercoagulable state. However, the approach used so far to the measure of clotting in sickle cell disease was segmented in the sense that the various components of the hemostatic balance were studied separately.The thrombin generation test is a functional test which explores the coagulation globally, integrating both pro players that anticoagulants actors in the system. The investigators already used this test to demonstrate that the hemostatic potential was high in a cohort of affected children compared to control children of the same age. This test will be used to characterize the hemostatic potential of adult sickle cell patients followed at the CHU Brugmann Hospital.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 1, 2015
Enrollment StartSep 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.8 years ago

Interventions

Blood sampling - healthy volunteersother

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

Blood sampling - sickle cell patients arm - stable conditionother

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

Blood sampling - sickle cell patients arm- exsanguinotransfusion neededother

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.

Blood sampling - sickle cell patients arm - vaso-occlusive crisis.other

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.